Skip to main content

Table 2 Clinicopathologic factors related to chronic lymphocytic thyroiditis in 172 patients with PTC

From: Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis

  CLT(-) CLT(+) Χ2/t-test P-value
Count % Count %
Gender
 Female 107 (13.7) 45 (6.3) 1.874 0.171
 Male 17 (86.3) 3 (93.8)   
Age (Mean ±S.D) 50.06±11.51   46.44±10.62   1.893 0.060
 < 45 39 (31.5) 21 (43.8) 2.304 0.129
 ≥ 45 85 (68.5) 27 (56.3)   
Tumor Size(mm)(Mean ±S.D) 0.92 ±0.73   0.88±0.69   0.383 0.702
 < 1.0 cm 90 (72.6) 34 (70.8) 0.908 0.635
 ≥ 1.0 cm 34 (27.4) 14 (29.2)   
Multifocality
 Absent 94 (75.8) 35 (72.9) 0.154 0.695
 Present 30 (24.2) 13 (27.1)   
Bilaterality
 Absent 101 (81.5) 38 (79.2) 0.117 0.733
 Present 23 (18.5) 10 (20.8)   
Extrathyroidal extension
 Absent 76 (61.3) 34 (70.8) 1.367 0.242
 Present 48 (38.7) 14 (29.2)   
Central LM metastasis
 Absent 66 (53.2) 32 (66.7) 2.550 0.110
 Present 58 (46.8) 16 (33.3)   
Lateral LM metastasis
 Absent 110 (88.7) 44 (91.7) 0.323 0.570
 Present 14 (11.3) 4 (8.3)   
TNM stage
 I & II 71 (57.3) 36 (75.0) 5.770 0.056
 III 40 (32.3) 11 (22.9)   
 IVa 13 (10.5) 1 (2.1)   
BRAF mutation
 Negative 22 (17.7) 20 (41.7) 10.732 0.001
 Positive 102 (82.3) 28 (58.3)   
  1. LN Lymph node, TNM Tumor/node/metastasis